Vaccines directed to langerhans cells
AssigneeBaylor Research Institute
InventorsJacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, Eynav Klechevsky, SangKon Oh
Life of this patent
Estimating the term…
Abstract
The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.
Claims7
An isolated Langerin binding antibody or antigen binding fragment thereof comprising:
- i) an antibody light chain variable domain comprising light chain complementarity regions CDR1L, CDR2L and CDR3L from SEQ ID NO:
- 2 and an antibody heavy chain variable domain comprising heavy chain complementarity regions CDR1H, CDR2H and CDR3H from SEQ ID NO:
- 4 or,
- ii) an antibody light chain variable domain comprising light chain complementarity regions CDR1L, CDR2L and CDR3L from SEQ ID NO:
- 6 and an antibody heavy chain variable domain comprising heavy chain complementarity regions CDR1H, CDR2H and CDR3H from SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.